Sumitomo Pharma America, Inc.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Sumitomo Pharma America, Inc.
RECRUITINGPhase 1 / Phase 2NCT06526819
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid...
Sponsor: Sumitomo Pharma America, Inc.Enrolling: 12010 locations
Solid Tumor
RECRUITINGPhase 1 / Phase 2NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.Enrolling: 60620 locations
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1
RECRUITINGPhase 1 / Phase 2NCT06891885
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years...
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts...
Sponsor: Sumitomo Pharma America, Inc.Enrolling: 121 location
Retinitis Pigmentosa